Immunomic Therapeutics opens Phase 1 trial of ITI-9001 for Japanese Red Cedar pollinosis
The company began recruiting for a first-in-human study testing its saRNA allergy immunotherapy in Japanese adults sensitized to Japanese Red Cedar pollen.
Immunomic Therapeutics registered one trial update during the week of July 24, 2026.
- ITI-9001, a Phase 1 first-in-human trial in Japanese patients with Japanese Red Cedar pollinosis, is listed as recruiting with an actual start date of 2026-06-201 and an estimated enrollment of 45 participants1. The trial is testing a self-amplifying RNA immunotherapy formulated with lipid nanoparticles that encodes a CryJ2-LAMP-1 fusion protein targeting Japanese Red Cedar pollen allergy1, with primary and study completion estimated for 2028-021.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.